DE-104 ophthalmic solution, low concentration + DE-104 ophthalmic solution, medium concentration + DE-104 ophthalmic solution, high concentration + DE-104 vehicle
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Open-Angle Glaucoma
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Trial Timeline
— → —
NCT ID
NCT00657579About DE-104 ophthalmic solution, low concentration + DE-104 ophthalmic solution, medium concentration + DE-104 ophthalmic solution, high concentration + DE-104 vehicle
DE-104 ophthalmic solution, low concentration + DE-104 ophthalmic solution, medium concentration + DE-104 ophthalmic solution, high concentration + DE-104 vehicle is a phase 2 stage product being developed by Santen Pharmaceutical for Open-Angle Glaucoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00657579. Target conditions include Open-Angle Glaucoma, Ocular Hypertension.
What happened to similar drugs?
5 of 19 similar drugs in Open-Angle Glaucoma were approved
Approved (5) Terminated (1) Active (13)
🔄Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)Mankind PharmaPhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00657579 | Phase 2 | Completed |
Competing Products
20 competing products in Open-Angle Glaucoma